The pharmacogenomics research team at Mayo Clinic is finding better ways to individualize drug treatment through information drawn from patients' genetic material.
Pharmacogenomics (the analyses of how genetic makeup affects an individual's response to drugs) gives providers the ability to choose the right drug and deliver it at the right time. The ability to predict which drugs will affect patients adversely also reduces side effects.
The pharmacogenomics research team at Mayo includes pathologists, scientists, bioethicists, genomic counselors, bioinformatic specialists, operations staff and medical professionals. Together, they conduct clinical trials related to cancers and coronary artery disease and work to translate that information into medical practice quickly. Their ultimate goal is to prevent the diseases that they currently treat.